Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ernexa Therapeutics (ERNA) Revenue (2016 - 2024)

Historic Revenue for Ernexa Therapeutics (ERNA) over the last 14 years, with Q4 2024 value amounting to $19000.0.

  • Ernexa Therapeutics' Revenue fell 6122.45% to $19000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $19000.0, marking a year-over-year decrease of 9698.41%. This contributed to the annual value of $600000.0 for FY2024, which is 50000.0% up from last year.
  • Ernexa Therapeutics' Revenue amounted to $19000.0 in Q4 2024, which was down 6122.45% from $487000.0 recorded in Q3 2024.
  • In the past 5 years, Ernexa Therapeutics' Revenue registered a high of $2.4 million during Q1 2020, and its lowest value of -$256000.0 during Q2 2023.
  • In the last 4 years, Ernexa Therapeutics' Revenue had a median value of $50000.0 in 2023 and averaged $519166.7.
  • In the last 5 years, Ernexa Therapeutics' Revenue tumbled by 172857.14% in 2023 and then skyrocketed by 85490.2% in 2024.
  • Over the past 4 years, Ernexa Therapeutics' Revenue (Quarter) stood at $1.2 million in 2020, then plummeted by 101.19% to -$14000.0 in 2022, then surged by 450.0% to $49000.0 in 2023, then tumbled by 61.22% to $19000.0 in 2024.
  • Its last three reported values are $19000.0 in Q4 2024, $487000.0 for Q3 2024, and $47000.0 during Q2 2024.